{
  "id": 20908695,
  "title": "Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen",
  "url": "https://urgent.news/2026/11/20/revolution-medicines-highlights-strong-12-month-overall-survival-rate",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-20T14:26:55.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/markets/biotech/26/11/63470724/revolution-medicines-highlights-strong-12-month-overall-survival-rate-for-lead-cancer-drug-regimen"
  },
  "original_language": "en",
  "account": null,
  "summary": "Revolution Medicines (RVMD) has released positive results from its Phase 1/2 RMC-GI-102 study on the combination of Rasonque (daraxonib) and gemcitabine/nab-paclitaxel as a potential first-line treatment for metastatic pancreatic adenocarcinoma (PDAC). The study, presented at the EORTC-NCI-AACR Symposium, showed a 76.6% 12-month overall survival rate in 61 patients who received the regimen, with a 60.7% objective response rate and a 90.2% disease control rate. The safety profile of the combination therapy remained consistent with previous data for both Rasonque and gemcitabine/nab-paclitaxel.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}